Reference:WMA Declaration of Helsinki 2024 34: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Gxplex admin (talk | contribs) m 1 revision imported Β |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:WMA Declaration of Helsinki 2024 | ||
| | |module=6 | ||
| | |unit=6.1.2 | ||
| | |scope=G | ||
| | |doc_part=34 | ||
| | |language=EN | ||
| | |entry_by=Florian Adragna | ||
|contributors= | |||
|tags=TAG-00270-Pos-chd ++ TAG-00017-Spo-die ++ TAG-00051-Eth-ngs ++ TAG-00025-Sub-mer | |||
|tags_display=[[Glossary:TAG-00270-Pos-chd|Post-trial access]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00051-Eth-ngs|Ethics]], [[Glossary:TAG-00025-Sub-mer|Trial participant]] | |||
|comment=Post-trial provisions: arrangements to be made in advance | |||
|content=Post-Trial Provisions | |||
34. In advance of a clinical trial, post-trial provisions must be arranged by sponsors and researchers to be provided by themselves, healthcare systems, or governments for all participants who still need an intervention identified as beneficial and reasonably safe in the trial. Exceptions to this requirement must be approved by a research ethics committee. Specific information about post-trial provisions must be disclosed to participants as part of informed consent. | |||
}} | }} | ||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | WMA Declaration of Helsinki 2024 |
| Validity area | WMA |
| Scope(s) | G |
| Document name | Declaration of Helsinki |
| Version / Revision | 2024 |
| Status | Current |
| Document type | International guideline |
| Language(s) | EN |
| Description | Declaration of Helsinki
Medical Research Involving Human Participants The Declaration of Helsinki (DoH) is the World Medical Associationβs (WMA) best-known policy statement. The first version was adopted in 1964 and has been amended seven times since, most recently at the General Assembly in October 2024. The current (2024) version is the only official one; all previous versions* have been replaced and should not be used or cited except for historical purposes. The WMA would like to thank all those who submitted comments and suggestions for the most recent revision of the DoH. |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 6 β Unit 6.1.2 |
| Scope | G |
| Document part | 34 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Post-trial access, Sponsor, Ethics, Trial participant |
Content
Post-Trial Provisions 34. In advance of a clinical trial, post-trial provisions must be arranged by sponsors and researchers to be provided by themselves, healthcare systems, or governments for all participants who still need an intervention identified as beneficial and reasonably safe in the trial. Exceptions to this requirement must be approved by a research ethics committee. Specific information about post-trial provisions must be disclosed to participants as part of informed consent.
